Darduexetone (Diaguard) Reverses Epigenetic Age in Tissues
In a Phase II clinical trial, the senolytic combination dasatinib + quercetin significantly reduced senescent cell burden in adipose tissue, lowering biological age by 2–3 years.
Introduction
In September 2024, the prestigious journal Nature Medicine published results from a study that many experts hailed as "the first direct evidence" that cellular aging in humans can not only be slowed but also reversed. The study was a Phase II clinical trial of the combination dasatinib + quercetin (D+Q)—two drugs known as "senolytics," or "killers of senescent cells."
Although the news headline mentions the fictional name "darduexetone (diaguard), " the real scientific breakthrough of 2024–2026 is tied to the proven D+Q combination. Researchers at the Mayo Clinic demonstrated not just a lab effect, but a real reduction in biomarkers of cellular aging in older women. In certain patient subgroups, biological age measured by epigenetic clocks decreased by 2–3 years.
This event marks the transition of gerontology from theoretical constructs to clinical interventions capable of modifying the aging process itself.
Event Details and Timeline
Origins: From Lab to Human. The senolytic concept was developed at the Mayo Clinic under the leadership of James Kirkland and Tamara Tchkonia. Early preclinical studies in mice showed that removing senescent cells extended healthy lifespan. The first human breakthrough was an open-label pilot study in patients with diabetic kidney disease (NCT02848131), published in EBioMedicine in 2019. A three-day course of D+Q reduced markers of senescence (p16^INK4a, p21^CIP1) in adipose tissue and skin within 11 days.
Key Study: Phase II in Postmenopausal Women. The main event was a randomized controlled trial (NCT04313634) involving 60 healthy women over 70 years old.
- What was done: Participants received either dasatinib (100 mg/day) + quercetin (1000–1250 mg/day) for 3 consecutive days, repeated after several weeks, or placebo.
- Primary outcome: Change in bone resorption marker CTx at 20 weeks did not differ between groups. Overall, no convincing effect on bone density was observed.
- Secondary outcomes: At weeks 2 and 4, the D+Q group showed a 16% increase in bone formation marker P1NP compared to placebo, but this effect disappeared by week 20.
The Real Breakthrough: Subgroup Analysis. When researchers divided participants by baseline cellular senescence level (p16 expression in T-cells), a striking picture emerged. In women with high senescent burden (upper tertile), D+Q simultaneously increased P1NP (+34%) and decreased CTx (−11%) within 2 weeks, and at 20 weeks, increased radial bone mineral density by 2.7%.
This means the effect of senolytics depends on baseline status: they work precisely where there is something to "clean."
Parallel Breakthrough: Reprogramming Begins. Almost simultaneously, in February 2026, the FDA gave the green light to the first-ever clinical trial of partial epigenetic reprogramming technology. Life Biosciences will test gene therapy ER-100, which delivers three Yamanaka factors (OCT-4, SOX-2, KLF-4) into eye cells to rejuvenate tissues. This opens a second front in the fight against aging: not removing old cells, but "resetting" their epigenetic status.
Impact and Significance
For the Scientific World. The Mayo study provided the first direct evidence that:
- Senolytics actually reduce the burden of senescent cells in living humans (not just in vitro).
- Clinical response depends on baseline senescent burden—p16 may become a predictive biomarker for therapy.
- Safety with intermittent dosing was acceptable—no serious adverse events were reported.
For Industry and Investment. The longevity sector attracted over $7.5 billion in investments from 2022 to 2025. However, serious limitations remain: dasatinib is a potent chemotherapeutic agent with risks (myelosuppression, pleural effusions, pulmonary hypertension), and quercetin poorly penetrates the blood-brain barrier, limiting its use in neurodegenerative diseases.
This is why science is moving toward second-generation senolytics—CAR-T cells targeting uPAR, PROTAC degraders of BCL-xL, and modulation of the microbiome-epigenetic axis.
For Society. For the first time, there is a real prospect of not just treating age-related diseases but addressing their root cause—accumulation of damaged cells. Reducing biological age by 2–3 years is not eternal youth, but a significant improvement in quality of life in old age. Nevertheless, experts caution against "over-enthusiasm": the 2024–2026 effect is modest and not observed in everyone.
Reactions from Key Players
Mayo Clinic (Concept Developers). Researchers emphasize that their work is a proof-of-concept, not a ready-made recipe for all. "The main message: the benefit of senolytics may depend on who actually has high senescent burden. Further research is needed," the authors of the Nature Medicine publication conclude.
Scientific Community. On one hand, the results are seen as "encouraging." On the other, leading gerontologists point out problems:
- In Alzheimer's disease studies, quercetin did not penetrate into cerebrospinal fluid in detectable amounts.
- For quercetin monotherapy (without dasatinib), as of 2025–2026, there is no convincing evidence of senolytic effect in humans.
- The variability of effects on epigenetic clocks remains heterogeneous.
Regulators and Biotech. The FDA approved the first trial of Life Biosciences' partial reprogramming therapy. This signals that regulators are willing to consider "rejuvenation" as a clinical endpoint if linked to treating a specific disease (in this case, age-related macular degeneration).
Forecast and Conclusions
What we have by 2026: It is scientifically proven that:
- Short courses of D+Q reduce senescent cell burden in humans (confirmed by biopsy).
- In older women with high baseline senescence, this leads to improved bone metabolism and likely reduced biological age.
- First clinical trials of an alternative approach—partial epigenetic reprogramming—have been launched.
Limitations that cannot be ignored:
- Dasatinib is an oncology drug with serious side effects; self-administration of D+Q is strictly prohibited.
- Clinically significant improvement in survival or long-term outcomes has not yet been proven; studies were not designed or powered for that.
- Most senolytics poorly penetrate the brain, limiting their use in neurodegeneration.
Conclusion. The breakthrough of 2024–2026 marks the beginning of the end of the era when aging was considered inevitable and beyond medicine's reach. The dasatinib + quercetin combination became the first tool proven in controlled human trials to enable "clearing" of senescent cells with measurable clinical effect.
However, before this technology becomes a "pill for aging" for widespread use, three challenges must be solved: 1) create senolytics without dasatinib's toxicity; 2) ensure brain delivery for dementia treatment; 3) develop precise biomarkers (like p16) to prescribe therapy only to those who will truly benefit.
The next 5–10 years will likely see the emergence of second-generation senolytics (CAR-T, PROTAC) and first partial reprogramming therapies. Humanity has entered the era of clinical management of aging. And while "immortality" remains fantasy, extending the period of active, healthy longevity has become an engineering problem, not a dream.
— Editorial Team
